查詢結果分析
來源資料
相關文獻
- 肢端肥大症
- 生長素對心臟血管系統的影響以及肢端肥大症影響呼吸道問題的解決
- Acromegaly with Pituitary Tumor Apoplexy: A Case Report
- ST-segment Elevation Acute Myocardial Infarction in a Patient with Acromegaly: A Case Report and Literature Review
- 肢端肥大症
- 肢端肥大症的診斷與治療
- 成人成長素缺乏需要補充治療嗎﹖
- 生長素受器拮抗劑之發展近況
- Hypopituitarism after Surgical Adenomectomy in Adult Patients with Acromegaly--A Review with Emphasis on Growth Hormone Deficiency
- 天麻活性成分對位羥基苯醇改善學習記憶作用與下視丘-腦下垂體-腎上腺軸之關係
頁籤選單縮合
題 名 | 肢端肥大症=Acromegaly |
---|---|
作 者 | 邱司漢; 黃立言; 孫毅麟; 譚光還; 黃毓龍; 石光中; | 書刊名 | 內科學誌 |
卷 期 | 22:1 2011.02[民100.02] |
頁 次 | 頁9-18 |
分類號 | 415.6631 |
關鍵詞 | 巨人症; 肢端肥大症; 生長素; 類胰島素生長因子-1; 垂體; Gigantism; Acromegaly; Growth hormone; Insulin-like growth factor 1; IGF-1; Pituitary; |
語 文 | 中文(Chinese) |
中文摘要 | 肢端肥大症(acromegaly) 是一罕見疾病,特徵是器官不正常的增生或肥大,尤其在四 肢和顏面。過量生長素(growth hormone, GH) 的分泌,在青春期之前,因骨骺尚未閉合, 因此會引起巨人症(gigantism);而在青春期之後,則會導致肢端肥大症。生長素分泌過多 的病程通常是緩慢的,其會逐漸影響代謝功能和生長發育。診斷標準包括了臨床症狀、生 化檢驗和影像發現。生化檢驗主要是生長素的濃度無法被葡萄糖所抑制( 生長素的濃度仍 然>1 ng/mL) 或類胰島素生長因子-1 (insulin-like growth factor 1, IGF-1) 超過正常值。治療 原則主要是減少生長素和 IGF-1 的分泌,如果病人罹患垂體腫瘤,則經蝶竇垂體腺瘤切除術 (trans-sphenoid pituitary adenomectomy) 應是治療的首選,以減少腫瘤的大小與分泌。如果外 科手術無法將生長素和 IGF-1 的濃度減至正常,則可考慮內科療法,治療藥物主要是體抑素 類似物(somatostatin analogues) 或合併放射治療。使用體抑素類似物出現明顯的抗性或副作用 時,則可考慮使用生長素受體拮抗劑(growth hormone receptor antagonist)。近年來,肢端肥大 症的病人在免疫系統、心血管系統、呼吸系統和代謝方面的預後,已有明顯改善。 |
英文摘要 | Acromegaly is a rare disease characterized by exaggerated somatic growth, especially involving the extremities and face, that is associated with systemic manifestations related to organ overgrowth. High exposure to growth hormone produces gigantism in youths prior to epiphyseal fusion and acromegaly in adults. Effects of hypersomatotrophism is characterized by slowly progressive acquired somatic disfigurement(mainly involving the acral and soft tissue growth)and metabolic function. The diagnostic criteria include clinical presentations, biochemical profiles and image findings. The laboratory data requires GH concentration unsuppressible by an oral glucose load (>1.0 ng/mL) or by detection of increased levels of insulin-like growth factor-I (IGF-I). A comprehensive strategy for treatment is aimed at management of the pituitary mass, and at reducing GH and IGF-I hypersecretion. Transsphenoidal surgery is generally the first-line treatment. If surgery fails to correct GH/IGF-I levels to normal values, medical treatment with somatostatin analogues and/or radiotherapy can be tried. The GH-receptor antagonist (pegvisomant)is used in patients with resistance to or intolerance of somatostatin analogues. The prognosis has improved in the recent years; it is definitive by rheumatologic, cardiovascular, respiratory and metabolic consequences. |
本系統中英文摘要資訊取自各篇刊載內容。